FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

On December 21, the FDA approved CD20xCD3 bispecific mosunetuzumab-axgb as a subcutaneous formulation for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy, based on results from the Phase I/II GO29781 study.

For more information, read the Genentech press release.

Posted on 2/2/2026